{
  "resourceType" : "ValueSet",
  "id" : "2.16.840.1.113883.3.464.1003.198.11.1142",
  "meta" : {
    "versionId" : "6",
    "lastUpdated" : "2019-03-15T01:00:14.000-04:00",
    "profile" : [
      "http://hl7.org/fhir/StructureDefinition/shareablevalueset",
      "http://hl7.org/fhir/us/cqfmeasures/StructureDefinition/publishable-valueset-cqfm"
    ]
  },
  "extension" : [
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-author",
      "valueString" : "NCQA PHEMUR Author"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/resource-lastReviewDate",
      "valueDate" : "2022-12-15"
    },
    {
      "url" : "http://hl7.org/fhir/StructureDefinition/valueset-effectiveDate",
      "valueDate" : "2019-03-15"
    }
  ],
  "url" : "http://cts.nlm.nih.gov/fhir/ValueSet/2.16.840.1.113883.3.464.1003.198.11.1142",
  "identifier" : [
    {
      "system" : "urn:ietf:rfc:3986",
      "value" : "urn:oid:2.16.840.1.113883.3.464.1003.198.11.1142"
    }
  ],
  "version" : "20190315",
  "name" : "OpiateAntagonists",
  "title" : "Opiate Antagonists",
  "status" : "active",
  "experimental" : false,
  "date" : "2019-03-15T01:00:14-04:00",
  "publisher" : "NCQA PHEMUR",
  "jurisdiction" : [
    {
      "extension" : [
        {
          "url" : "http://hl7.org/fhir/StructureDefinition/data-absent-reason",
          "valueString" : "UNKNOWN"
        }
      ]
    }
  ],
  "purpose" : "(Clinical Focus: ),(Data Element Scope: ),(Inclusion Criteria: ),(Exclusion Criteria: )",
  "compose" : {
    "include" : [
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "concept" : [
          {
            "code" : "HZ90ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Nicotine Replacement"
          },
          {
            "code" : "HZ91ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Methadone Maintenance"
          },
          {
            "code" : "HZ92ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Levo-alpha-acetyl-methadol (LAAM)"
          },
          {
            "code" : "HZ93ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Antabuse"
          },
          {
            "code" : "HZ94ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Naltrexone"
          },
          {
            "code" : "HZ95ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Naloxone"
          },
          {
            "code" : "HZ96ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Clonidine"
          },
          {
            "code" : "HZ97ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Bupropion"
          },
          {
            "code" : "HZ98ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication"
          },
          {
            "code" : "HZ99ZZZ",
            "display" : "Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication"
          }
        ]
      }
    ]
  },
  "expansion" : {
    "identifier" : "urn:uuid:59b1b9f6-f81a-465b-b601-d1f550b8bdb5",
    "timestamp" : "2023-06-29T19:01:24-04:00",
    "total" : 10,
    "offset" : 0,
    "parameter" : [
      {
        "name" : "count",
        "valueInteger" : 1000
      },
      {
        "name" : "offset",
        "valueInteger" : 0
      }
    ],
    "contains" : [
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ90ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Nicotine Replacement"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ91ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Methadone Maintenance"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ92ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Levo-alpha-acetyl-methadol (LAAM)"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ93ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Antabuse"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ94ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Naltrexone"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ95ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Naloxone"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ96ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Clonidine"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ97ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Bupropion"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ98ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Psychiatric Medication"
      },
      {
        "system" : "http://www.cms.gov/Medicare/Coding/ICD10",
        "version" : "2023",
        "code" : "HZ99ZZZ",
        "display" : "Pharmacotherapy for Substance Abuse Treatment, Other Replacement Medication"
      }
    ]
  }
}
